GlassScriptPhysician profile
Sheldon A Zitman
NPI 1184722332
$2,195.75
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2020: $399 · 2021: $19.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $299.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $273.34 | 2019-2020 | |
| Pfizer INC. | $262.27 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.31 | 2019-2020 | |
| Allergan, INC. | $136.96 | 2019-2020 | |
| Mylan Specialty L.P. | $113.32 | 2019 | |
| Merck Sharp & Dohme LLC | $109.90 | 2019 | |
| Lilly USA, LLC | $92.58 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $91.92 | 2019 | |
| Glaxosmithkline, LLC. | $68.79 | 2019-2020 | |
| Amgen INC. | $64.72 | 2019-2020 | |
| Abbvie INC. | $60.63 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $59.46 | 2019-2020 | |
| Seqirus USA INC | $47.23 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.80 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42.40 | 2020 | |
| Genentech USA, INC. | $40.41 | 2019 | |
| Philips North America LLC | $40.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.22 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.77 | 2019-2020 | |
| Becton, Dickinson and Company | $23.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.37 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.17 | 2019 | |
| Amarin Pharma, INC. | $20.68 | 2019 | |
| Novo Nordisk INC | $16.82 | 2020 | |
| Sanofi Pasteur INC. | $10.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Zitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.